See more : GreenX Metals Limited (GRX.WA) Income Statement Analysis – Financial Results
Complete financial analysis of WuXi AppTec Co., Ltd. (WUXIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of WuXi AppTec Co., Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Sysgration Ltd. (5309.TWO) Income Statement Analysis – Financial Results
- Amedisys, Inc. (AMED) Income Statement Analysis – Financial Results
- Jay Shree Tea & Industries Limited (JAYSHREETEA.BO) Income Statement Analysis – Financial Results
- Nickel Creek Platinum Corp. (NCP.TO) Income Statement Analysis – Financial Results
- Komputronik S.A. (KOM.WA) Income Statement Analysis – Financial Results
WuXi AppTec Co., Ltd. (WUXIF)
About WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.34B | 39.35B | 22.90B | 16.54B | 12.87B | 9.61B | 7.77B | 6.12B | 4.88B | 4.14B |
| Cost of Revenue | 23.77B | 24.68B | 14.59B | 10.25B | 7.86B | 5.82B | 4.52B | 3.62B | 3.20B | 2.62B |
| Gross Profit | 16.57B | 14.68B | 8.31B | 6.28B | 5.01B | 3.79B | 3.25B | 2.49B | 1.69B | 1.52B |
| Gross Profit Ratio | 41.09% | 37.30% | 36.28% | 37.99% | 38.95% | 39.45% | 41.83% | 40.76% | 34.55% | 36.78% |
| Research & Development | 1.44B | 1.61B | 942.24M | 693.26M | 590.39M | 436.53M | 611.30M | 214.36M | 143.12M | 129.61M |
| General & Administrative | 905.56M | 927.22M | 766.15M | 508.56M | 509.14M | 395.51M | 11.55M | 314.81M | 217.07M | 694.92M |
| Selling & Marketing | 188.00M | 731.59M | 698.97M | 588.46M | 438.54M | 337.88M | 291.51M | 200.44M | 185.81M | 132.15M |
| SG&A | 1.09B | 1.66B | 1.47B | 1.10B | 947.68M | 733.39M | 303.06M | 515.25M | 402.87M | 827.07M |
| Other Expenses | 2.21B | 736.87M | -107.23M | -11.03M | -288.76M | 611.75M | 132.03M | 97.57M | 29.67M | 110.09M |
| Operating Expenses | 4.74B | 4.93B | 3.65B | 2.95B | 2.39B | 1.83B | 1.49B | 1.25B | 1.18B | 829.84M |
| Cost & Expenses | 28.47B | 29.61B | 18.24B | 13.20B | 10.25B | 7.65B | 6.00B | 4.88B | 4.38B | 3.45B |
| Interest Income | 444.47M | 190.85M | 191.69M | 92.36M | 88.21M | 12.19M | 7.89M | 12.02M | 10.90M | 182.68M |
| Interest Expense | 74.82M | 159.84M | 128.33M | 196.03M | 128.02M | 92.41M | 48.55M | 16.36M | 28.13M | 0.00 |
| Depreciation & Amortization | 2.28B | 1.69B | 1.29B | 1.00B | 841.17M | 544.41M | 402.78M | 344.98M | 326.93M | -154.24M |
| EBITDA | 14.17B | 12.42B | 7.37B | 4.51B | 3.26B | 3.22B | 2.04B | 1.57B | 1.16B | 692.75M |
| EBITDA Ratio | 35.12% | 32.46% | 31.61% | 27.87% | 25.83% | 33.68% | 28.36% | 29.11% | 24.28% | 17.10% |
| Operating Income | 11.87B | 10.65B | 6.04B | 3.39B | 2.34B | 2.58B | 1.46B | 1.28B | 771.68M | 861.96M |
| Operating Income Ratio | 29.43% | 27.07% | 26.36% | 20.50% | 18.19% | 26.89% | 18.81% | 21.00% | 15.80% | 20.82% |
| Total Other Income/Expenses | -40.29M | -33.77M | -22.12M | -20.11M | -3.96M | -3.88M | 132.03M | 97.57M | 29.67M | 106.73M |
| Income Before Tax | 11.83B | 10.62B | 6.02B | 3.37B | 2.34B | 2.58B | 1.59B | 1.38B | 801.35M | 968.69M |
| Income Before Tax Ratio | 29.33% | 26.98% | 26.27% | 20.38% | 18.16% | 26.85% | 20.51% | 22.60% | 16.41% | 23.40% |
| Income Tax Expense | 2.13B | 1.72B | 879.66M | 383.13M | 425.56M | 247.14M | 295.90M | 261.20M | 117.57M | 160.58M |
| Net Income | 9.61B | 8.81B | 5.10B | 2.96B | 1.85B | 2.26B | 1.23B | 974.98M | 348.97M | 461.50M |
| Net Income Ratio | 23.81% | 22.40% | 22.26% | 17.90% | 14.41% | 23.51% | 15.80% | 15.94% | 7.15% | 11.15% |
| EPS | 3.24 | 3.01 | 1.75 | 1.06 | 0.68 | 0.95 | 0.56 | 0.46 | 0.17 | 0.22 |
| EPS Diluted | 3.24 | 2.82 | 1.73 | 1.05 | 0.67 | 0.94 | 0.55 | 0.46 | 0.17 | 0.22 |
| Weighted Avg Shares Out | 2.97B | 3.13B | 2.91B | 2.79B | 2.75B | 2.39B | 2.20B | 2.12B | 2.10B | 2.13B |
| Weighted Avg Shares Out (Dil) | 2.97B | 3.13B | 2.95B | 2.82B | 2.78B | 2.40B | 2.22B | 2.72B | 2.72B | 2.13B |
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
WuXi AppTec to raise $500 mln in convertible bond sale as US restrictions loom
US bill to restrict business with China's WuXi AppTec, BGI passes House
US House committee to vote on bill to restrict BGI, WuXi AppTec
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties
Exclusive: China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators
US Senate committee takes up bill targeting China's BGI, WuXi Apptec
China's WuXi AppTec says it poses no national security risks to US
Source: https://incomestatements.info
Category: Stock Reports